Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Rating Lowered by Wall Street Zen

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. reduced their price objective on shares of Enanta Pharmaceuticals from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a report on Wednesday, September 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Thursday, October 15th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $19.00.

View Our Latest Stock Report on Enanta Pharmaceuticals

Enanta Pharmaceuticals Trading Down 4.5%

Shares of Enanta Pharmaceuticals stock opened at $7.62 on Friday. The company has a 50-day simple moving average of $11.48 and a two-hundred day simple moving average of $12.97. Enanta Pharmaceuticals has a one year low of $7.56 and a one year high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.09). Enanta Pharmaceuticals had a negative net margin of 108.33% and a negative return on equity of 59.48%. The firm had revenue of $12.87 million during the quarter, compared to the consensus estimate of $14.62 million. As a group, sell-side analysts anticipate that Enanta Pharmaceuticals will post -2.24 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Jupiter Topco LLC purchased a new position in shares of Enanta Pharmaceuticals in the 2nd quarter valued at approximately $53,252,000. BlackRock Inc. acquired a new stake in Enanta Pharmaceuticals in the 2nd quarter worth approximately $47,304,000. ADAR1 Capital Management LLC acquired a new stake in Enanta Pharmaceuticals in the 2nd quarter worth approximately $19,603,000. Spruce Street Capital LP purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $15,873,698. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Enanta Pharmaceuticals during the 2nd quarter worth approximately $2,231,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Key Headlines Impacting Enanta Pharmaceuticals

These are some of the ENTA headlines that stood out recently:

  • Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target, while raising its FY2027–FY2030 earnings estimates to reflect smaller projected losses. This signals improved longer-term expectations, though the forecasts still show losses. MarketBeat report
  • Neutral Sentiment: JPMorgan cut its price target to $17 from $19 but kept an Overweight rating. The lower target is a negative revision, while the rating and implied upside from the cited $7.62 share price remain supportive.
  • Negative Sentiment: Enanta’s latest reported quarter missed expectations: its loss per share was wider than analysts forecast, and revenue came in below estimates. The results may weigh on sentiment amid the analyst updates. MarketBeat earnings information

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc. is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology. Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

Featured Stories

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.